Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation and Safety Study of HBI0101 CART in B-cell Mediated Refractory Autoimmune Diseases

NCT07085676 is registered in ClinicalTrials.gov with Polina Stepensky as lead sponsor.

NCT NCT07085676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07085676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation and Safety Study of HBI0101 CART in B-cell Mediated Refractory Autoimmune Diseases
Lead sponsor
Polina Stepensky
Phase
Phase 1
Overall status
Recruiting
Start date
September 1, 2024
Completion date
November 1, 2030
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiphospholipid antibody syndrome, idiopathic inflammatory myopathy (iim), multiple sclerosis (ms) primary progressive, multiple sclerosis (ms) secondary progressive, myasthenia gravis (mg), neuromyelitis optica spectrum disorder (nmosd), rheumatoid arthritis (ra), systemic lupus erythematosus (sle), systemic sclerosis (ssc)